著者

兵頭 洋二 宍戸 清一郎 河村 毅 櫻林 啓 新津 靖雄 二瓶 大 青木 裕次郎 村松 真樹 酒井 謙 相川 厚

出版者

一般社団法人 日本移植学会

雑誌

移植 (ISSN:05787947)

巻号頁・発行日

vol.48, no.1, pp.042-047, 2013-03-10 (Released:2014-10-03)

参考文献数

10

---

【Objective】The purpose of this study was to evaluate pharmacokinetic (Pk) profile of newly developed modified release tacrolimus (MR-TAC) in pediatric kidney transplant recipients.【Methods】According to our current immunosuppressive protocol, tacrolimus (TAC) was initially given and converted to MR-TAC in 13 pediatric patients who received kidney transplantation from April 2010 to April 2011. The switch dose ratio was 1:1, and the 24hour full Pk study was assessed before and after the conversion from TAC to MR-TAC.【Results】The mean total daily dose at baseline upon enrollment was 5.4±3.3 mg. There was no significant correlation between the oral dose and the trough concentration (C0) of TAC/MR-TAC. The consecutive Pk studies revealed no significant difference in the mean time to maximum concentration (Tmax) / maximum concentration (Cmax) and the area under the time-concentration curve (AUC0-24) of both reagents; the mean C0 of MR-TAC was 18% lower than those of TAC. A better correlation between AUC0-24 and C0 was observed in MR-TAC compared to that in TAC (r2=0.912, for MR-TAC; r2>0.555, for TAC). 【Conclusion】In the conversion from TAC to MR-TAC, AUC0-24 was equivalent despite the 18% reduction of C0, even in the pediatric kidney transplant recipients. The trough concentration might be an excellent predictor in the therapeutic drug monitoring of MR-TAC because of its better correlation of C0 and AUC0-24.

著者

桑原 達朗 酒井 謙 河村 毅 宍戸 清一郎 水入 苑生 長谷川 昭 相川 厚 定本 清美

出版者

日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集

巻号頁・発行日

vol.20, 2010-10-25

著者

宍戸 清一郎 早川 正道 比嘉 功 小山 雄三 秦野 直 大澤 炯

出版者

泌尿器科紀要刊行会

雑誌

泌尿器科紀要 (ISSN:00181994)

巻号頁・発行日

vol.36, no.4, pp.401-405, 1990-04

---

From March, 1986 through June, 1988, the reduced M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimen was used to treat 6 patients with metastatic or locally invasive transitional cell carcinoma of renal pelvis and ureter. Out of 5 evaluable patients with advanced stages (N+ and/or M+) pathological complete remission and partial remission were observed in one patient each and minor remission in two patients inspite of our reduced regimen according to performance status of the patients. Toxicity was rather mild except in one patient who showed severe myelosuppression. This regimen seems to give favorable antitumor activity against transitional cell carcinoma of upper urothelium.